Achieve Life Sciences' NDA for cytisinicline received a Complete Response Letter (CRL) from the FDA.
2 reports, 1 independent
Updated Aug 11
Gone quiet
Reached 2 outlets in its first 24 hours
- Reports
- 2
- Developments
- 1
- Repetition
- 50%
New informationRepeats or wire copies
AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.
What happened
Achieve Life Sciences' NDA for cytisinicline received a Complete Response Letter (CRL) from the FDA.
Who's involved
What this event is mainly aboutKeep exploring
The entities involved
Related events
- Cronus Pharma LLC, headquartered in East Brunswick, is launching products in the U.S. market and seeking FDA approval.
- Kroger, based in Cincinnati, is under FDA review due to a cyclospora outbreak.
- Ensysce Biosciences, listed on Nasdaq, acquired Cy Biopharma, and representatives presented at a public FDA hearing.
- FDA issued a Complete Response Letter (CRL) regarding Disc Medicine, Inc.'s bitopertin program.
- FDA accepted Milestone's response to the Complete Response Letter (CRL).